149 related articles for article (PubMed ID: 27533878)
1. Detection of Occult Invasion in Melanoma In Situ.
Bax MJ; Johnson TM; Harms PW; Schwartz JL; Zhao L; Fullen DR; Chan MP
JAMA Dermatol; 2016 Nov; 152(11):1201-1208. PubMed ID: 27533878
[TBL] [Abstract][Full Text] [Related]
2. Melan-A positive dermal cells in malignant melanoma in situ.
Danga ME; Yaar R; Bhawan J
J Cutan Pathol; 2015 Jun; 42(6):388-93. PubMed ID: 25726939
[TBL] [Abstract][Full Text] [Related]
3. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes.
Willis BC; Johnson G; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):109-12. PubMed ID: 25356946
[TBL] [Abstract][Full Text] [Related]
4. Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas.
Drabeni M; Lopez-Vilaró L; Barranco C; Trevisan G; Gallardo F; Pujol RM
Am J Dermatopathol; 2013 Feb; 35(1):56-63. PubMed ID: 22688397
[TBL] [Abstract][Full Text] [Related]
5. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of MITF, SOX10, MART-1, and R21 Immunostaining for the Diagnosis of Residual Melanoma In Situ on Chronically Sun-Damaged Skin.
Mu EW; Quatrano NA; Yagerman SE; Ratner D; Meehan SA
Dermatol Surg; 2018 Jul; 44(7):933-938. PubMed ID: 29419543
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of epithelial and melanocitic markers with double sequential immunohistochemical staining in differentiating melanoma in situ from invasive melanoma.
Parra-Medina R; Morales SD
Ann Diagn Pathol; 2017 Feb; 26():70-74. PubMed ID: 27594302
[TBL] [Abstract][Full Text] [Related]
8. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ.
Kim J; Taube JM; McCalmont TH; Glusac EJ
J Cutan Pathol; 2011 Oct; 38(10):775-9. PubMed ID: 21797920
[TBL] [Abstract][Full Text] [Related]
9. SOX10 Immunostaining in granulomatous dermatoses and benign reactive lymph nodes.
Merelo Alcocer V; Flamm A; Chen G; Helm K
J Cutan Pathol; 2019 Aug; 46(8):586-590. PubMed ID: 30957251
[TBL] [Abstract][Full Text] [Related]
10. Consecutive Immunohistochemical Staining on a Single Slide is Effective in Confirming Melanocytic Derivation.
Campbell KK; Gardner JM; Hall K; Osborne A; Shalin SC
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):e76-e81. PubMed ID: 30499815
[TBL] [Abstract][Full Text] [Related]
11. Three Types of Nodal Melanocytic Nevi in Sentinel Lymph Nodes of Patients With Melanoma: Pitfalls, Immunohistochemistry, and a Review of the Literature.
Gonzàlez-Farré M; Ronen S; Keiser E; Prieto VG; Aung PP
Am J Dermatopathol; 2020 Oct; 42(10):739-744. PubMed ID: 32271206
[TBL] [Abstract][Full Text] [Related]
12. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.
Magro CM; Yang SE; Zippin JH; Zembowicz A
Arch Pathol Lab Med; 2012 Dec; 136(12):1558-64. PubMed ID: 23194049
[TBL] [Abstract][Full Text] [Related]
13. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy.
Li LX; Scolyer RA; Ka VS; McKinnon JG; Shaw HM; McCarthy SW; Thompson JF
Am J Surg Pathol; 2003 Sep; 27(9):1197-202. PubMed ID: 12960803
[TBL] [Abstract][Full Text] [Related]
14. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.
Kucher C; Zhang PJ; Pasha T; Elenitsas R; Wu H; Ming ME; Elder DE; Xu X
Am J Dermatopathol; 2004 Dec; 26(6):452-7. PubMed ID: 15618925
[TBL] [Abstract][Full Text] [Related]
15. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
16. SOX-10 staining in dermal scars.
Behrens EL; Boothe W; D'Silva N; Walterscheid B; Watkins P; Tarbox M
J Cutan Pathol; 2019 Aug; 46(8):579-585. PubMed ID: 30950082
[TBL] [Abstract][Full Text] [Related]
17. Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology.
Dermawan JKT; Underwood D; Policarpio-Nicolas ML
Diagn Cytopathol; 2019 Jul; 47(7):653-658. PubMed ID: 30794352
[TBL] [Abstract][Full Text] [Related]
18. Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.
Viray H; Bradley WR; Schalper KA; Rimm DL; Gould Rothberg BE
Arch Pathol Lab Med; 2013 Aug; 137(8):1063-73. PubMed ID: 23899062
[TBL] [Abstract][Full Text] [Related]
19. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
20. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
